Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04467411 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The EMBRACE Study The EMBRACE Study

Study acronym: EMBRACE
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 1 to 2
    v6
  2. Trial status: Active, Not Recruiting to Recruiting
    • Enrollment target: 12 to 70
    • Site details revised
    • Study title shortened, about 13 words
    v5
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v4
  4. Primary and study completion dates: Jan 31, 2022 to Aug 30, 2030v3
  5. Primary and study completion dates: Jan 31, 2021 to Jan 31, 2022v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Cardiomyopathy is a condition that affects the heart muscle, whereby it becomes enlarged, thick or rigid. When the heart muscle becomes involved, it affects the pumping action of the heart. This condition can affect as many as 10% of all patients after undergoing anthracycline cancer drug therapy and unfortunately carries the worst prognosis of all cardiomyopathies. To date, there is no effective intervention that will prevent a patient from developing this condition. The research conducted will look to see if an energy imbalance in the heart predates the onset of detrimental changes to the pumping function of the heart, if this is detected then we can act earlier to prevent the pumping function deteriorating.
Trial Details
NCT Number NCT04467411
Lead Sponsor University of Aberdeen
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov